Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 330

Sort by

Sort Order Select

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma

Boheng Li, Junli Yan, The Phyu, Shuangyi Fan, Tae-Hoon Chung, Nurulhuda Mustafa, Baohong Lin, Lingzhi Wang, Pieter Johan Adam Eichhorn, Boon-Cher Goh, Siok-Bian Ng, Dennis Kappei, Wee-Joo Chng

Blood (2019) 134 (23): 2046–2058.

https://doi.org/10.1182/blood.2019000381

Published: 2019

Includes: Supplemental data

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

Journal Articles

Integrated Epigenetic Profiling Identifies EZH2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression

Valentina Gambacorta, MSc, Daniela Gnani, PhD, Laura Zito, MSc, Stefano Beretta, PhD, Lucia Zanotti, PhD, Oliveira Giacomo, PhD, Davide Cittaro, PhD, Ivan Merelli, PhD, Fabio Ciceri, MD, Raffaella Di Micco, PhD, Luca Vago, MD PhD

Blood (2019) 134 (Supplement_1): 514.

https://doi.org/10.1182/blood-2019-127395

Published: 2019

Journal Articles

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

Destini Gibbs, Herman Van Besien, BA, Stephenson Regan, Ankur Singh, PhD, Matthew Teater, Ethel Cesarman, MD PhD, Ari Melnick, MD, Lisa Giulino Roth, MD

Blood (2019) 134 (Supplement_1): 304.

https://doi.org/10.1182/blood-2019-126790

Published: 2019

Journal Articles

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

Pukhraz Basra, MBBS, David Gajzer, MD, Mohammad O Hussaini, MD, Hailing Zhang, MD, Lynn C. Moscinski, MD, Eric Padron, MD, David A Sallman, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Jinming Song, MD PhD

Blood (2019) 134 (Supplement_1): 5428.

https://doi.org/10.1182/blood-2019-132070

Published: 2019

Journal Articles

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

Myrna Candelaria, MD PharmD, Adriana Palacios Campos, MD, Olga Gutierrez Hernandez, QFB, Alejandro Aviles, MD, Uvi Cancino-Ramos, MD, Lucia Taja Chayeb, PhD, Osvaldo García-Perez, MD, David Cantú de León

Blood (2019) 134 (Supplement_1): 5222.

https://doi.org/10.1182/blood-2019-125906

Published: 2019

Journal Articles

HO-1 Promotes Resistance to EZH2 Inhibitor through the Prb-E2F Pathway: Corelated with the Conversion of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Zhengchang He, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 5401.

https://doi.org/10.1182/blood-2019-131573

Published: 2019

Journal Articles

Histone Modifications in Development and Malignancy

Elisa Oricchio, DPhil

Blood (2019) 134 (Supplement_1): SCI-49.

https://doi.org/10.1182/blood-2019-121289

Published: 2019

Journal Articles

Synthetic Lethality-Based Approach Identified EED and BRD4 As Critical Survival Factorsin Acte Myeloid Leukemia with Monosomy 7

Kensuke Matsuda, MD, Yuki Kagoya, MD PhD, Sho Yamazaki, MD PhD, Masashi Miyauchi, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 1233.

https://doi.org/10.1182/blood-2019-123595

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

Mohamed Rizk, BSc, MSc, Ola Rizq, MD PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Shuhei Koide, PhD, Atsunori Saraya, Yusuke Isshiki, MD PhD, Tetsuhiro Chiba, MD PhD, Satoshi Yamazaki, PhD, Anqi Ma, PhD, Jian Jin, PhD, Atsushi Iwama, MD PhD, Naoya Mimura, MD PhD

Blood (2019) 134 (Supplement_1): 4400.

https://doi.org/10.1182/blood-2019-122157

Published: 2019

Journal Articles

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Ali Sakhdari, MD MSc, Caleb Class, PhD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Joseph D. Khoury, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, L. Jeffrey Medeiros, MD, Rashmi Kanagal-Shamanna, MD

Blood (2019) 134 (Supplement_1): 3016.

https://doi.org/10.1182/blood-2019-131774

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

Ezh1 Inhibits Commitment to Hemogenic Fate and HSPC Formation during Vertebrate Development

Rebecca Soto, BS, Edroaldo Lummertz da rocha, PhD, Linda T Vo, PhD, Mariam Hachimi, PhD, Jenna M Frame, PhD, Paul J. Wrighton, PhD, Wolfram Goessling, MD PhD, George Q. Daley, MD PhD, Trista E North, PhD

Blood (2019) 134 (Supplement_1): 3710.

https://doi.org/10.1182/blood-2019-131464

Published: 2019

Journal Articles

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

Blood (2019) 134 (Supplement_1): 3758.

https://doi.org/10.1182/blood-2019-126910

Published: 2019

Journal Articles

New Insights into PLZF/Rara Mechanism during APL Onset: EZH2 on the Road

Mathilde Poplineau, Nadine Platet, PhD, Lia N'Guyen, Shuhei Koide, PhD, Julien Vernerey, PhD, Yaeko Nakajima-Takagi, PhD, Motohiko Oshima, PhD, Atsushi Iwama, MD PhD, Estelle Duprez, PhD

Blood (2019) 134 (Supplement_1): 3761.

https://doi.org/10.1182/blood-2019-125509

Published: 2019

Journal Articles

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Wendy Béguelin, PhD, Matthew R Teater, PhD, Cem Meydan, PhD, Jude M Phillip, PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2768.

https://doi.org/10.1182/blood-2019-132263

Published: 2019

Journal Articles

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Daniel Bottomly, Nicola Long, Fei Yang, MD, Tiffany Lee, MD, Uma Borate, MD, Beth Wilmot, PhD, Adam S DuVall, MD, Andrea Monteblanco, BS, Karina Thiel-Klare, Gabby Dewson, BA, Richard D. Press, MD PhD, Cristina E. Tognon, Brian J. Druker, Jeffrey W. Tyner, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2019) 134 (Supplement_1): 1407.

https://doi.org/10.1182/blood-2019-132224

Published: 2019

NARROW

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Integrated Epigenetic Profiling Identifies EZH2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

HO-1 Promotes Resistance to EZH2 Inhibitor through the Prb-E2F Pathway: Corelated with the Conversion of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Histone Modifications in Development and Malignancy

Synthetic Lethality-Based Approach Identified EED and BRD4 As Critical Survival Factorsin Acte Myeloid Leukemia with Monosomy 7

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Ezh1 Inhibits Commitment to Hemogenic Fate and HSPC Formation during Vertebrate Development

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

New Insights into PLZF/Rara Mechanism during APL Onset: EZH2 on the Road

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only